Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Identifieur interne : 000F13 ( Main/Exploration ); précédent : 000F12; suivant : 000F14Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Auteurs : Francesco Ceppi [Canada] ; Michel Duval ; Pierre Teira ; Roxane Therrien ; Philippe Ovetchkine ; Brigitte Mallette ; Henrique BittencourtSource :
- Journal of pediatric hematology/oncology [ 1536-3678 ] ; 2014.
Descripteurs français
- KwdFr :
- Acide mycophénolique (analogues et dérivés), Acide mycophénolique (usage thérapeutique), Anticorps monoclonaux d'origine murine (pharmacologie), Antinéoplasiques (pharmacologie), Association thérapeutique (MeSH), Calcineurine (MeSH), Conditionnement pour greffe (MeSH), Enfant (MeSH), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Leucémie-lymphome lymphoblastique à précurseurs T (complications), Leucémie-lymphome lymphoblastique à précurseurs T (thérapie), Maladie du greffon contre l'hôte (prévention et contrôle), Mâle (MeSH), Pronostic (MeSH), Rituximab (MeSH), Résistance aux médicaments antinéoplasiques (MeSH), Sirolimus (usage thérapeutique), Syndromes lymphoprolifératifs (thérapie), Syndromes lymphoprolifératifs (étiologie), Transplantation de cellules souches hématopoïétiques (effets indésirables), Transplantation homologue (MeSH), Vidarabine (analogues et dérivés), Vidarabine (usage thérapeutique).
- MESH :
- analogues et dérivés : Acide mycophénolique, Vidarabine.
- effets indésirables : Leucémie-lymphome lymphoblastique à précurseurs T, Transplantation de cellules souches hématopoïétiques.
- pharmacologie : Anticorps monoclonaux d'origine murine, Antinéoplasiques.
- prévention et contrôle : Maladie du greffon contre l'hôte.
- thérapie : Leucémie-lymphome lymphoblastique à précurseurs T, Syndromes lymphoprolifératifs.
- usage thérapeutique : Acide mycophénolique, Immunosuppresseurs, Sirolimus, Vidarabine.
- étiologie : Syndromes lymphoprolifératifs.
- Association thérapeutique, Calcineurine, Conditionnement pour greffe, Enfant, Humains, Mâle, Pronostic, Rituximab, Résistance aux médicaments antinéoplasiques, Transplantation homologue.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Murine-Derived (pharmacology), Antineoplastic Agents (pharmacology), Calcineurin (MeSH), Child (MeSH), Combined Modality Therapy (MeSH), Drug Resistance, Neoplasm (MeSH), Graft vs Host Disease (prevention & control), Hematopoietic Stem Cell Transplantation (adverse effects), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Lymphoproliferative Disorders (etiology), Lymphoproliferative Disorders (therapy), Male (MeSH), Mycophenolic Acid (analogs & derivatives), Mycophenolic Acid (therapeutic use), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (complications), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (therapy), Prognosis (MeSH), Rituximab (MeSH), Sirolimus (therapeutic use), Transplantation Conditioning (MeSH), Transplantation, Homologous (MeSH), Vidarabine (analogs & derivatives), Vidarabine (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Mycophenolic Acid, Vidarabine.
- chemical , pharmacology : Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents.
- chemical , therapeutic use : Immunosuppressive Agents, Mycophenolic Acid, Sirolimus, Vidarabine.
- chemical : Calcineurin, Rituximab.
- adverse effects : Hematopoietic Stem Cell Transplantation.
- complications : Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
- etiology : Lymphoproliferative Disorders.
- prevention & control : Graft vs Host Disease.
- therapy : Lymphoproliferative Disorders, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
- Child, Combined Modality Therapy, Drug Resistance, Neoplasm, Humans, Male, Prognosis, Transplantation Conditioning, Transplantation, Homologous.
Abstract
Posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. We describe here the case of a boy with history of induction failure of a T-cell acute lymphoblastic leukemia, who presented a life-threatening situation of nonengraftment and rituximab-refractory PTLD after the first hematopoietic stem cell transplantation. We decided to use an unusual strategy of combining a nonmyeloablative conditioning (fludarabine and cyclophosphamide) with a calcineurin inhibitor-free GvHD prophylaxis (sirolimus and mycophenolate mofetil). This strategy had permitted the control of an Epstein-Barr virus PLTD in umbilical cord blood transplantation without further reactivation.
DOI: 10.1097/MPH.0000000000000066
PubMed: 24977404
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.</title><author><name sortKey="Ceppi, Francesco" sort="Ceppi, Francesco" uniqKey="Ceppi F" first="Francesco" last="Ceppi">Francesco Ceppi</name><affiliation wicri:level="3"><nlm:affiliation>*Department of Pediatrics, Division of Hematology-Oncology, Centre de Cancérologie Charles-Bruneau †Department of Pharmacy ‡Department of Pediatrics, Division of Infectious Disease §Department of Microbiology, Laboratory of Molecular Virology and Serology, University of Montreal, Sainte Justine Hospital, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>*Department of Pediatrics, Division of Hematology-Oncology, Centre de Cancérologie Charles-Bruneau †Department of Pharmacy ‡Department of Pediatrics, Division of Infectious Disease §Department of Microbiology, Laboratory of Molecular Virology and Serology, University of Montreal, Sainte Justine Hospital, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Duval, Michel" sort="Duval, Michel" uniqKey="Duval M" first="Michel" last="Duval">Michel Duval</name></author><author><name sortKey="Teira, Pierre" sort="Teira, Pierre" uniqKey="Teira P" first="Pierre" last="Teira">Pierre Teira</name></author><author><name sortKey="Therrien, Roxane" sort="Therrien, Roxane" uniqKey="Therrien R" first="Roxane" last="Therrien">Roxane Therrien</name></author><author><name sortKey="Ovetchkine, Philippe" sort="Ovetchkine, Philippe" uniqKey="Ovetchkine P" first="Philippe" last="Ovetchkine">Philippe Ovetchkine</name></author><author><name sortKey="Mallette, Brigitte" sort="Mallette, Brigitte" uniqKey="Mallette B" first="Brigitte" last="Mallette">Brigitte Mallette</name></author><author><name sortKey="Bittencourt, Henrique" sort="Bittencourt, Henrique" uniqKey="Bittencourt H" first="Henrique" last="Bittencourt">Henrique Bittencourt</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24977404</idno><idno type="pmid">24977404</idno><idno type="doi">10.1097/MPH.0000000000000066</idno><idno type="wicri:Area/Main/Corpus">000E20</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E20</idno><idno type="wicri:Area/Main/Curation">000E20</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E20</idno><idno type="wicri:Area/Main/Exploration">000E20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.</title><author><name sortKey="Ceppi, Francesco" sort="Ceppi, Francesco" uniqKey="Ceppi F" first="Francesco" last="Ceppi">Francesco Ceppi</name><affiliation wicri:level="3"><nlm:affiliation>*Department of Pediatrics, Division of Hematology-Oncology, Centre de Cancérologie Charles-Bruneau †Department of Pharmacy ‡Department of Pediatrics, Division of Infectious Disease §Department of Microbiology, Laboratory of Molecular Virology and Serology, University of Montreal, Sainte Justine Hospital, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>*Department of Pediatrics, Division of Hematology-Oncology, Centre de Cancérologie Charles-Bruneau †Department of Pharmacy ‡Department of Pediatrics, Division of Infectious Disease §Department of Microbiology, Laboratory of Molecular Virology and Serology, University of Montreal, Sainte Justine Hospital, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Duval, Michel" sort="Duval, Michel" uniqKey="Duval M" first="Michel" last="Duval">Michel Duval</name></author><author><name sortKey="Teira, Pierre" sort="Teira, Pierre" uniqKey="Teira P" first="Pierre" last="Teira">Pierre Teira</name></author><author><name sortKey="Therrien, Roxane" sort="Therrien, Roxane" uniqKey="Therrien R" first="Roxane" last="Therrien">Roxane Therrien</name></author><author><name sortKey="Ovetchkine, Philippe" sort="Ovetchkine, Philippe" uniqKey="Ovetchkine P" first="Philippe" last="Ovetchkine">Philippe Ovetchkine</name></author><author><name sortKey="Mallette, Brigitte" sort="Mallette, Brigitte" uniqKey="Mallette B" first="Brigitte" last="Mallette">Brigitte Mallette</name></author><author><name sortKey="Bittencourt, Henrique" sort="Bittencourt, Henrique" uniqKey="Bittencourt H" first="Henrique" last="Bittencourt">Henrique Bittencourt</name></author></analytic><series><title level="j">Journal of pediatric hematology/oncology</title><idno type="eISSN">1536-3678</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived (pharmacology)</term><term>Antineoplastic Agents (pharmacology)</term><term>Calcineurin (MeSH)</term><term>Child (MeSH)</term><term>Combined Modality Therapy (MeSH)</term><term>Drug Resistance, Neoplasm (MeSH)</term><term>Graft vs Host Disease (prevention & control)</term><term>Hematopoietic Stem Cell Transplantation (adverse effects)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Lymphoproliferative Disorders (etiology)</term><term>Lymphoproliferative Disorders (therapy)</term><term>Male (MeSH)</term><term>Mycophenolic Acid (analogs & derivatives)</term><term>Mycophenolic Acid (therapeutic use)</term><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (complications)</term><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (therapy)</term><term>Prognosis (MeSH)</term><term>Rituximab (MeSH)</term><term>Sirolimus (therapeutic use)</term><term>Transplantation Conditioning (MeSH)</term><term>Transplantation, Homologous (MeSH)</term><term>Vidarabine (analogs & derivatives)</term><term>Vidarabine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide mycophénolique (analogues et dérivés)</term><term>Acide mycophénolique (usage thérapeutique)</term><term>Anticorps monoclonaux d'origine murine (pharmacologie)</term><term>Antinéoplasiques (pharmacologie)</term><term>Association thérapeutique (MeSH)</term><term>Calcineurine (MeSH)</term><term>Conditionnement pour greffe (MeSH)</term><term>Enfant (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Leucémie-lymphome lymphoblastique à précurseurs T (complications)</term><term>Leucémie-lymphome lymphoblastique à précurseurs T (thérapie)</term><term>Maladie du greffon contre l'hôte (prévention et contrôle)</term><term>Mâle (MeSH)</term><term>Pronostic (MeSH)</term><term>Rituximab (MeSH)</term><term>Résistance aux médicaments antinéoplasiques (MeSH)</term><term>Sirolimus (usage thérapeutique)</term><term>Syndromes lymphoprolifératifs (thérapie)</term><term>Syndromes lymphoprolifératifs (étiologie)</term><term>Transplantation de cellules souches hématopoïétiques (effets indésirables)</term><term>Transplantation homologue (MeSH)</term><term>Vidarabine (analogues et dérivés)</term><term>Vidarabine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mycophenolic Acid</term><term>Vidarabine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term><term>Mycophenolic Acid</term><term>Sirolimus</term><term>Vidarabine</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calcineurin</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Hematopoietic Stem Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide mycophénolique</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs T</term><term>Transplantation de cellules souches hématopoïétiques</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphoproliferative Disorders</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine</term><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Graft vs Host Disease</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Maladie du greffon contre l'hôte</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lymphoproliferative Disorders</term><term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs T</term><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide mycophénolique</term><term>Immunosuppresseurs</term><term>Sirolimus</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Combined Modality Therapy</term><term>Drug Resistance, Neoplasm</term><term>Humans</term><term>Male</term><term>Prognosis</term><term>Transplantation Conditioning</term><term>Transplantation, Homologous</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association thérapeutique</term><term>Calcineurine</term><term>Conditionnement pour greffe</term><term>Enfant</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Rituximab</term><term>Résistance aux médicaments antinéoplasiques</term><term>Transplantation homologue</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. We describe here the case of a boy with history of induction failure of a T-cell acute lymphoblastic leukemia, who presented a life-threatening situation of nonengraftment and rituximab-refractory PTLD after the first hematopoietic stem cell transplantation. We decided to use an unusual strategy of combining a nonmyeloablative conditioning (fludarabine and cyclophosphamide) with a calcineurin inhibitor-free GvHD prophylaxis (sirolimus and mycophenolate mofetil). This strategy had permitted the control of an Epstein-Barr virus PLTD in umbilical cord blood transplantation without further reactivation. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24977404</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3678</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of pediatric hematology/oncology</Title><ISOAbbreviation>J Pediatr Hematol Oncol</ISOAbbreviation></Journal><ArticleTitle>Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.</ArticleTitle><Pagination><MedlinePgn>e319-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MPH.0000000000000066</ELocationID><Abstract><AbstractText>Posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. We describe here the case of a boy with history of induction failure of a T-cell acute lymphoblastic leukemia, who presented a life-threatening situation of nonengraftment and rituximab-refractory PTLD after the first hematopoietic stem cell transplantation. We decided to use an unusual strategy of combining a nonmyeloablative conditioning (fludarabine and cyclophosphamide) with a calcineurin inhibitor-free GvHD prophylaxis (sirolimus and mycophenolate mofetil). This strategy had permitted the control of an Epstein-Barr virus PLTD in umbilical cord blood transplantation without further reactivation. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceppi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>*Department of Pediatrics, Division of Hematology-Oncology, Centre de Cancérologie Charles-Bruneau †Department of Pharmacy ‡Department of Pediatrics, Division of Infectious Disease §Department of Microbiology, Laboratory of Molecular Virology and Serology, University of Montreal, Sainte Justine Hospital, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Teira</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Therrien</LastName><ForeName>Roxane</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ovetchkine</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mallette</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bittencourt</LastName><ForeName>Henrique</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr Hematol Oncol</MedlineTA><NlmUniqueID>9505928</NlmUniqueID><ISSNLinking>1077-4114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D019703">Calcineurin</NameOfSubstance></Chemical><Chemical><RegistryNumber>FA2DM6879K</RegistryNumber><NameOfSubstance UI="D014740">Vidarabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>P2K93U8740</RegistryNumber><NameOfSubstance UI="C024352">fludarabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019703" MajorTopicYN="Y">Calcineurin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006086" MajorTopicYN="N">Graft vs Host Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008232" MajorTopicYN="N">Lymphoproliferative Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054218" MajorTopicYN="N">Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014740" MajorTopicYN="N">Vidarabine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24977404</ArticleId><ArticleId IdType="doi">10.1097/MPH.0000000000000066</ArticleId><ArticleId IdType="pii">00043426-201407000-00032</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement></list><tree><noCountry><name sortKey="Bittencourt, Henrique" sort="Bittencourt, Henrique" uniqKey="Bittencourt H" first="Henrique" last="Bittencourt">Henrique Bittencourt</name><name sortKey="Duval, Michel" sort="Duval, Michel" uniqKey="Duval M" first="Michel" last="Duval">Michel Duval</name><name sortKey="Mallette, Brigitte" sort="Mallette, Brigitte" uniqKey="Mallette B" first="Brigitte" last="Mallette">Brigitte Mallette</name><name sortKey="Ovetchkine, Philippe" sort="Ovetchkine, Philippe" uniqKey="Ovetchkine P" first="Philippe" last="Ovetchkine">Philippe Ovetchkine</name><name sortKey="Teira, Pierre" sort="Teira, Pierre" uniqKey="Teira P" first="Pierre" last="Teira">Pierre Teira</name><name sortKey="Therrien, Roxane" sort="Therrien, Roxane" uniqKey="Therrien R" first="Roxane" last="Therrien">Roxane Therrien</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Ceppi, Francesco" sort="Ceppi, Francesco" uniqKey="Ceppi F" first="Francesco" last="Ceppi">Francesco Ceppi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24977404
|texte= Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24977404" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |